Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Puma Biotechnology Inc    PBYI

SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets
The feature you requested does not exist. However, we suggest the following feature:

PUMA BIOTECHNOLOGY, INC. (NYSE:PBYI) Files An 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

share with twitter share with LinkedIn share with facebook
share via e-mail
0
12/20/2016 | 01:38pm CEST

PUMA BIOTECHNOLOGY, INC. (NYSE:PBYI) Files An 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Item3.01

Notice of Delisting or Failure to Satisfy a Continued
Listing Rule or Standard; Transfer of Listing.

On December15, 2016, the Board of Directors of Puma
Biotechnology, Inc. (the Company) authorized the Company to
transfer the listing of its common stock, par value $0.0001 per
share (Common Stock), from The New York Stock Exchange (the NYSE)
to The NASDAQ Stock Market (NASDAQ). On December19, 2016, the
Company provided written notice to the NYSE of its intention to
voluntarily delist its Common Stock from the NYSE and to list its
Common Stock on NASDAQ. The Company expects the listing and
trading of its Common Stock on the NYSE to cease at the close of
trading on December30, 2016 and that trading of its Common stock
will commence on NASDAQ on the next business day, January3, 2017.
The Companys Common Stock has been approved for listing on NASDAQ
and will continue to trade under the stock symbol PBYI.

A copy of the press release issued by the Company in connection
with the transfer of the listing of its Common Stock from the
NYSE to NASDAQ is attached hereto as Exhibit 99.1 and is
incorporated herein by reference.

Item9.01 Financial Statements and Exhibits.
(d) Exhibits.
99.1 Press Release dated December19, 2016

About PUMA BIOTECHNOLOGY, INC. (NYSE:PBYI)
Puma Biotechnology, Inc. is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the global development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), which the Company is developing for the treatment of patients with human epidermal growth factor receptor type 2 (HER2), positive breast cancer, and patients with non-small cell lung cancer, breast cancer and other solid tumors that have a HER2 mutation; PB272 (neratinib (intravenous)), which the Company is developing for the treatment of patients with advanced cancer, and PB357, which is an orally administered agent. Neratinib is a potent irreversible tyrosine kinase inhibitor (TKI) that blocks signal transduction through the epidermal growth factor receptors (EGFRs), HER1, HER2 and HER4. PUMA BIOTECHNOLOGY, INC. (NYSE:PBYI) Recent Trading Information
PUMA BIOTECHNOLOGY, INC. (NYSE:PBYI) closed its last trading session down -1.20 at 35.05 with 539,945 shares trading hands.

The post PUMA BIOTECHNOLOGY, INC. (NYSE:PBYI) Files An 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing appeared first on Market Exclusive.

© Market Exclusive 2016, source Market Exclusive

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on PUMA BIOTECHNOLOGY INC
09/22 PUMA BIOTECHNOLOGY : SEC Issues Administrative Proceeding on Joel P. Zingerman
09/21 PUMA BIOTECHNOLOGY : US Oncology Research Plays an Important Role in the Clinica..
09/18 PUMA BIOTECHNOLOGY : to Present at Cantor Fitzgerald Healthcare Conference
09/13 PUMA BIOTECHNOLOGY : US Oncology Research Plays Important Role in Clinical Devel..
09/09 PUMA BIOTECHNOLOGY : Biotech (PBYI) Presents 5-Year Analysis of Phase III ExteNE..
09/08 PUMA BIOTECHNOLOGY, INC. : Other Events (form 8-K)
09/08 PUMA BIOTECHNOLOGY : Presents 5-Year Analysis of Phase III ExteNET Trial in Exte..
09/07 PUMA BIOTECHNOLOGY : to Participate in Panel Discussion at Citi's Biotech Confer..
09/06 PUMA BIOTECHNOLOGY : Ogallala woman participates in cancer drug trial
09/05 PUMA BIOTECHNOLOGY : Ogallala woman participates in cancer drug trial
More news
News from SeekingAlpha
01/03 Adam Feuerstein's 17 thoughts for biotech in 17
2016 Mid-stage data on therapeutic approach to managing neratinib-associated diarr..
2016 PREMARKET GAINERS / LOSERS AS OF 9 : 10 am
2016 Puma Bio launches ex-U.S. patient access program for neratinib
2016 INVESTOR SENTIMENT VS. SELLSIDE CONS : A Chicken And Egg Situation
Financials ($)
Sales 2017 16,1 M
EBIT 2017 -320 M
Net income 2017 -330 M
Finance 2017 70,3 M
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales 2017 237x
EV / Sales 2018 19,6x
Capitalization 3 888 M
Chart PUMA BIOTECHNOLOGY INC
Duration : Period :
Puma Biotechnology Inc Technical Analysis Chart | PBYI | US74587V1070 | 4-Traders
Technical analysis trends PUMA BIOTECHNOLOGY INC
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
 
Mean consensus OUTPERFORM
Number of Analysts 9
Average target price 115 $
Spread / Average Target 9,7%
EPS Revisions
Managers
NameTitle
Alan H. Auerbach Chairman, President, CEO & Secretary
Charles R. Eyler Treasurer & Senior VP-Finance & Administration
Richard Paul Bryce Chief Medical & Scientific Officer
Jay M. Moyes Independent Director
Troy E. Wilson Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
PUMA BIOTECHNOLOGY INC2.61%3 888
INCYTE CORPORATION14.74%23 351
QUINTILES IMS HOLDINGS INC23.89%20 370
LONZA GROUP56.52%19 634
CELLTRION, INC.--.--%15 568
ALNYLAM PHARMACEUTICALS, INC.201.60%10 439